Condiciones de salud que resveratrol puede ayudar a apoyar.
Resveratrol has been studied in a single-blind, vehicle-controlled pilot clinical trial for acne vulgaris, showing a 53.75% mean reduction in global acne grading score (GAGS) vs. 6.10% for vehicle, and a 66.7% mean reduction in microcomedone area on histologic analysis. It inhibits C. acnes biofilm formation and has anti-inflammatory and anti-androgenic properties.
Resveratrol, a polyphenol from plants including Polygonum cuspidatum and grapes, is identified in peer-reviewed reviews as possessing ALS activity through antioxidant and anti-neuroinflammatory mechanisms. It inhibits pro-inflammatory cytokines in microglial cells and was among top-performing antioxidant compounds in an in vitro ALS motor neuron screening assay. Evidence is primarily preclinical.
Resveratrol, a polyphenolic stilbenoid found in grapes, berries, and red wine, has documented antioxidant mechanisms including direct free-radical scavenging and upregulation of the Nrf2/Keap1 antioxidant transcription pathway. Human clinical trials have been conducted, with some showing improvement in antioxidant markers (notably glutathione peroxidase and total antioxidant capacity at higher doses), though results across trials are mixed and no consistent, conclusive benefit has been established. The evidence base is scientific in character but limited by small sample sizes and heterogeneous study designs.
Resveratrol activates SIRT1 and eNOS, increasing endothelial NO production and improving arterial vasodilation. Clinical trials show it improves endothelial function and reduces markers of oxidative stress and arterial inflammation. A 2024 umbrella meta-analysis of RCTs confirmed modest but significant vascular improvements including reductions in diastolic blood pressure.
Resveratrol has been tested in human RCTs for knee osteoarthritis and studied mechanistically in rheumatoid arthritis cell models. The ARTHROL Phase 3 RCT (n=142, double-blind, 6 months) assessed oral resveratrol versus placebo for painful knee OA at three French tertiary centers. Preclinical and in vitro data robustly show resveratrol inhibits NF-κB and activates SIRT1 to suppress inflammatory cytokines in articular cartilage and synovial cells.
Resveratrol, a stilbenoid polyphenol from grapes and berries, has demonstrated immunomodulatory and anti-inflammatory properties in autoimmune disease models and clinical trials. It inhibits NF-κB, promotes Treg cells, and suppresses Th17 responses. Human RCTs in SLE patients have shown reductions in disease activity and inflammatory biomarkers.
Resveratrol inhibits platelet MAP kinase signaling, modulates oxidative stress and inflammatory cytokines, and has demonstrated antithrombotic effects relevant to venous thromboembolism in preclinical models. A 2025 systematic review confirmed resveratrol prevents and attenuates DVT and PE through antioxidant, anti-inflammatory, and anticoagulant mechanisms, though controlled human trials are lacking.
Resveratrol, a polyphenolic stilbene from grapes and red wine, has been tested in multiple RCTs for blood pressure reduction. A systematic review and meta-analysis found significant diastolic blood pressure reduction, with evidence for both SBP and DBP effects in specific dosing ranges. It modulates NO bioavailability and vascular oxidative stress.
Resveratrol, a polyphenol found in grapes and berries, has been evaluated in multiple RCTs for glycemic control in T2DM. A meta-analysis of 15 RCTs (896 T2DM patients) found resveratrol significantly improved insulin resistance (HOMA-IR, WMD: −0.99, p=0.002). It activates SIRT1 and AMPK pathways to enhance insulin sensitivity.
Multiple human RCTs demonstrate that resveratrol supplementation can improve bone mineral density (BMD), particularly in postmenopausal women. The 24-month RESHAW trial (75 mg twice daily) showed significant gains in lumbar spine and femoral neck BMD alongside a 7.24% reduction in bone resorption marker CTX-1 versus placebo. A separate RCT in type 2 diabetic patients found resveratrol 500 mg/day prevented whole-body BMD loss seen in placebo recipients. Results across studies are inconsistent but the highest-quality data support a modest bone-protective effect.
Resveratrol is cited by Severn Pain and Injury Care for bursitis inflammation reduction. It attenuates inflammation by inhibiting TNF-α, IL-1β, IL-6, and NF-κB. A network meta-analysis found resveratrol more effective than placebo for reducing DAS28 in RA. An RCT in endurance athletes found resveratrol reduced inflammatory markers post-exercise.
Resveratrol, the polyphenol stilbenoid found in grapes and Japanese knotweed, has demonstrated antifungal activity against Candida albicans in vitro by inhibiting the yeast-to-hyphal morphological switch and disrupting fungal cell membrane function. It is included in some Candida cleanse protocols as a supplementary antifungal and antioxidant.
Resveratrol is a polyphenolic stilbene that inhibits NF-κB signaling, suppresses MMP-13 and ADAMTS-5, and activates SIRT1, collectively reducing inflammatory cartilage degradation in OA. Multiple in vitro and animal studies confirm chondroprotective effects. A clinical pilot RCT found intra-articular resveratrol reduced cartilage loss in an animal OA model, and an early human placebo-controlled pilot trial found resveratrol 1000 mg/day for 6 months reduced WOMAC pain scores and cartilage degradation biomarkers.
Resveratrol activates AMPK and SIRT1/SIRT3, two master regulators of cellular energy metabolism, in human tissue. Ex vivo studies on human skeletal muscle confirm AMPK/SIRT1 pathway activation after acute resveratrol dosing. In human vascular endothelial cells, resveratrol promotes mitochondrial biogenesis and ATP synthesis via the AMPK–PGC-1α–SIRT3 pathway.
Resveratrol, a stilbene polyphenol from grapes, reduces proliferation, induces apoptosis, and decreases HPV E6/E7 oncoprotein expression while increasing p53 in multiple cervical cancer cell lines. In vivo animal studies show reduced tumor volume. No completed human RCT data for cervical dysplasia specifically exist; resveratrol is a component of the TriCurin combination being developed for HPV+ cervical dysplasia trials.
Resveratrol reduces TC, LDL-C, and triglycerides through inhibition of cholesterol ester formation, increased bile acid excretion, and oxidized LDL reduction. A meta-analysis of 17 RCTs (968 participants) found significant TC (−0.27 mmol/L), TG (−0.10 mmol/L), and LDL-C (−0.147 mmol/L) reductions with a dose-dependent response.
Resveratrol is a polyphenol from grapes and other plants with documented effects on mitochondrial biogenesis via SIRT1/PGC-1α activation. Clinical evidence shows resveratrol improves metabolic function and reduces fatigue in certain clinical populations. Animal studies consistently show improved endurance and reduced fatigue markers.
Resveratrol, a polyphenolic compound found in grapes and berries, has documented anti-inflammatory activity supported by multiple randomized controlled trials and meta-analyses in humans. Clinical meta-analyses confirm significant reductions in key inflammatory biomarkers—particularly TNF-α and hs-CRP—following supplementation. Results across studies are promising but show meaningful heterogeneity, and no consensus dosing regimen has been established for any specific inflammatory condition.
Resveratrol, a stilbenoid polyphenol from grapes and red wine, supports vascular circulation by stimulating endothelial nitric oxide synthase (eNOS), reducing oxidative stress, inhibiting platelet aggregation, and improving arterial compliance. Clinical trial results on vascular biomarkers are contrasting and often null at high supplemental doses; effects from food-source (red wine) consumption at lower doses have shown significant improvements in endothelial function.
Resveratrol, a polyphenol found in grapes and red wine, has been investigated in multiple human randomized controlled trials for its potential to slow cognitive decline and support healthy aging. Clinical evidence shows it can improve cerebral blood flow, modulate Alzheimer's disease biomarkers (particularly CSF Aβ40), and in some trials improve memory and activities of daily living. However, results across trials are mixed, with several studies showing no significant improvement in standard cognitive scores (e.g., MMSE), and one large trial noting an unexpected increase in brain volume loss. Overall, the human evidence is promising but inconsistent, and larger, well-powered trials are needed.
Resveratrol has been comprehensively reviewed as an anti-HSV nutraceutical agent. Multiple in vitro studies demonstrate marked inhibition of HSV-1 and HSV-2 replication via AMPK activation and NF-κB suppression. It showed activity against acyclovir-resistant HSV strains. A 2018 PMC review synthesized available evidence for its mechanisms and anti-HSV efficacy.
Resveratrol, a polyphenol stilbene, has been tested in RCTs for ulcerative colitis. A meta-analysis of polyphenol RCTs confirmed resveratrol-containing preparations reduced clinical activity in UC and improved remission rates. It inhibits NF-κB and NLRP3 inflammasome activation in the colonic mucosa.
Resveratrol is a polyphenol stilbenoid that inhibits MMPs degrading connective tissue ECM, activates SIRT1 (influencing collagen gene expression), and reduces inflammatory cytokines that damage cartilage and connective tissue. It has been studied in pseudoachondroplasia (a connective tissue collagen disorder) and OA. Emerging data support co-supplementation with collagen for connective tissue benefits.
Resveratrol is a polyphenol evaluated in COPD for its anti-inflammatory and mitochondrial effects. A 2025 meta-analysis found resveratrol significantly downregulated serum TNF-α and IL-8 in COPD patients. The CARMENS trial (Maastricht University Medical Center) investigated resveratrol's effect on mitochondrial function in COPD. Preclinical rat models also show antioxidant and anti-inflammatory activity in cigarette smoke-induced COPD models.
Resveratrol is a polyphenol with documented tyrosinase-inhibiting and anti-melanogenic properties relevant to periorbital hyperpigmentation. A PMC review on natural hyperpigmentation treatments lists stilbenoids (including resveratrol) among active agents with relevant anti-melanogenic mechanisms. Resveratrol inhibits tyrosinase, suppresses MITF, and provides antioxidant protection to periorbital skin.
Resveratrol is identified in the 2025 narrative review on polyphenols in diverticular disease as a relevant bioactive compound offering antioxidant and anti-inflammatory protection potentially applicable to SUDD management. It inhibits NF-κB, reduces IBD-associated mucosal inflammation in animal models, and addresses the oxidative stress pathophysiology now recognized as central to diverticular disease progression.
Resveratrol is a polyphenol phytoalexin studied for antiangiogenic, anti-inflammatory, and pro-apoptotic effects in endometriosis models. A small randomized clinical trial found resveratrol (40 mg/day) combined with oral contraceptives reduced dysmenorrhea pain scores more than contraceptives alone. Animal studies consistently show reduced lesion vascularization and size.
Resveratrol has been investigated as adjunctive therapy for epilepsy due to its neuroprotective and antioxidant properties. Animal studies show that resveratrol pretreatment significantly attenuates mitochondrial complex I dysfunction and oxidative stress during status epilepticus. It is included among natural interventions that may benefit epileptic patients in clinical protocol literature, with mechanistic evidence from preclinical models.
Resveratrol is a stilbene phytoestrogen that binds ERα as a pathway-selective ligand, modulating inflammatory responses without stimulating breast or uterine cell proliferation. It also inhibits aromatase and steroidogenic enzymes, affecting plasma estrogen levels. PMC-published clinical trials show resveratrol plus equol improves bone turnover biomarkers in postmenopausal women.
Resveratrol activates SIRT1/AMPK pathways in testicular tissue, protecting sperm from oxidative stress and supporting testosterone synthesis. Multiple animal studies document improvements in sperm count, motility, and morphology. A pilot human study reported improvements in sperm quality markers. It is particularly studied for protective effects against environmental toxin-induced and heat-induced spermatogenic damage.
Human RCTs show resveratrol can increase cerebral blood flow and improve memory performance, particularly in older adults. A crossover RCT found dose-dependent increases in prefrontal cerebral blood flow during cognitive tasks after single doses of resveratrol. The RESHAW 24-month trial in postmenopausal women reported improvements in cognitive performance. Clinical translation remains limited by low bioavailability and mixed results across studies.
Resveratrol is a polyphenol stilbenoid with multiple preclinical studies demonstrating neuroprotection of retinal ganglion cells in glaucoma models. It reduces oxidative stress, neuroinflammation, and RGC apoptosis in animal models of elevated IOP and retinal ischemia. A 2026 review (PMC13091925) identifies resveratrol among the nutraceuticals with the most compelling glaucoma evidence.
Resveratrol, a polyphenol found in grapes and other plants, has been shown in rodent studies to increase portal GLP-1 and insulin concentrations. It is listed among natural compounds with compelling evidence for GLP-1 activity in peer-reviewed reviews.
Resveratrol has been mechanistically characterized as a xanthine oxidase inhibitor in a 2025 study using kinetics, molecular docking, and animal models, showing reduced serum uric acid in hyperuricemic animals. It suppresses NLRP3 inflammasome and NF-κB in MSU crystal-induced gout models. Polygonum cuspidatum, the primary resveratrol source in TCM, showed the strongest XO inhibitory activity of Chinese anti-gout plant water extracts tested.
Resveratrol has been shown in clinical RCTs to slow periodontal disease progression and reduce probing pocket depth when used as an adjunct to SRP. A 2021 meta-analysis found resveratrol supplementation with SRP significantly improved probing pocket depth vs. SRP alone. Preclinical research confirms it reduces crestal bone loss and downregulates key inflammatory mediators in periodontal tissues.
Resveratrol is a stilbene polyphenol with well-documented gut microbiota-modulating effects, including promoting Lactobacillus and Bifidobacterium growth, inhibiting pathogenic E. coli, and stimulating SCFA (butyrate) production. A systematic review of its microbiome effects and multiple mechanistic studies confirm its prebiotic-like activity.
Resveratrol is a polyphenol that activates sirtuins and AMPK, pathways linked to caloric restriction and longevity. Multiple preclinical studies demonstrate lifespan extension in model organisms, and human trials show improvements in metabolic biomarkers and cardiovascular health. Meta-analyses support its role in suppressing oxidative stress and inflammation associated with aging.
Resveratrol, a polyphenol found in grape and other plants, has demonstrated protective effects against age-related ocular diseases through antioxidant inhibition of reactive oxygen species in human lens epithelial cells and retinal cells. A rodent study demonstrated that oral resveratrol improved lens elasticity—directly relevant to presbyopia—and retinal antioxidant capacity. It is identified by ocular health authorities as a natural intervention supporting aging eye health.
A meta-analysis of 36 RCTs (PubMed, 2018) found resveratrol significantly reduced body weight, BMI, fat mass, and waist circumference while increasing lean mass versus placebo, with the strongest effects seen in obese subjects. However, a separate meta-analysis found no significant effect on body weight or BMI, highlighting high heterogeneity. Results across trials are inconsistent, and clinical effect sizes are modest.
Resveratrol activates SIRT1 in the cochlea, reducing oxidative stress and promoting recovery from noise-induced hearing loss. PubMed studies in C57BL/6 mice show long-term resveratrol supplementation resulted in better hearing recovery and less hair cell loss after intense noise exposure. Resveratrol also has protective effects against cisplatin- and aminoglycoside-induced hearing loss.
Resveratrol, a polyphenol found in grapes and berries, has been extensively studied for cardiovascular benefits. Preclinical evidence is robust, showing protective effects against atherosclerosis, hypertension, and ischemic heart disease. Human clinical trials exist but have yielded mixed results, with the strongest signal being improvement in endothelial function (flow-mediated dilation); effects on blood pressure and lipids remain inconsistent across RCTs. Overall, clinical evidence is promising but not yet conclusive.
Resveratrol inhibits HSV-1 and HSV-2 replication in a dose-dependent manner in vitro by suppressing NF-κB activation and viral immediate-early gene expression. Topical resveratrol application reduced lesion severity and viral titers in a murine HSV-2 model. A 2018 PMC review characterized resveratrol as a novel anti-HSV nutraceutical agent.
Resveratrol is a polyphenol stilbene that has shown favorable effects on serum homocysteine in clinical trials, according to a 2021 systematic review (PMC8196702). Both animal studies and clinical trials demonstrate homocysteine-lowering effects, though results are not uniform across all studies. Resveratrol's mechanism may involve activation of SIRT1 and modulation of methylation pathways.
Resveratrol is a polyphenol from grapes and berries that supports hormone detoxification by reducing adduct formation from genotoxic 4-OH estrogen metabolites and supporting Phase II hepatic glucuronidation. Research shows it acts as a mixed estrogen receptor agonist/antagonist. Combined with NAC, it more effectively reduces quinone formation from harmful estrogen metabolites than either compound alone.
Small human RCTs indicate resveratrol may reduce hot flash frequency and severity in perimenopausal and menopausal women through phytoestrogenic and vasodilatory mechanisms. A pilot randomized, placebo-controlled study in 80 perimenopausal women found 150 mg/day for 12 weeks reduced hot flash frequency by approximately 30% versus placebo. Evidence is preliminary due to small sample sizes.
Resveratrol inhibits tyrosinase activity and suppresses cellular melanin production in vitro, and is used as a coadjuvant in hyperpigmentation treatments. It is listed in multiple dermatological reviews as a naturally occurring depigmenting agent, though it is not potent enough for monotherapy.
Resveratrol, a polyphenol from grape skin and red wine, activates SIRT1 and AMPK in skeletal muscle, improving insulin sensitivity by promoting GLUT4 translocation and glucose uptake. Multiple cell and animal studies confirm reversal of insulin resistance; human evidence shows metabolic benefits including improved mitochondrial capacity, though direct insulin sensitivity improvement in clinical trials is less consistent.
Resveratrol is a stilbene polyphenol found in grapes, red wine, and Japanese knotweed with documented anti-inflammatory effects on the intestinal barrier. Multiple authoritative reviews specifically list resveratrol among polyphenols intensely studied for leaky gut-related diseases. It modulates intestinal tight junction proteins and reduces gut inflammation through SIRT1 and NF-κB pathway modulation.
In vitro studies in 3T3-L1 adipocytes show resveratrol reduces leptin mRNA expression and secretion while increasing adiponectin. Animal studies in diet-induced obese rats demonstrate resveratrol improves peripheral leptin signaling/sensitivity via STAT3 pathways. Human RCT evidence on leptin and ghrelin specifically is limited and inconsistent, with metabolic benefits more consistently observed in animal and cellular models.
Multiple human RCTs have evaluated resveratrol for non-alcoholic fatty liver disease (NAFLD), with a comprehensive review identifying its potential for reducing liver fat accumulation and modulating liver enzyme levels. A meta-analysis of placebo-controlled trials found resveratrol had negligible overall effects on NAFLD markers in clinical studies, though preclinical evidence of hepatoprotection is robust. Results in humans are inconsistent across trials.
Resveratrol is a polyphenol stilbene with preclinical evidence for COPD and asthma. It activates SIRT1 in lung tissue, reducing cigarette smoke-induced NF-κB activation and oxidative stress. It is included in the Herbal Medicine for COPD review as a pharmacologically relevant compound.
Resveratrol, the primary polyphenol of Japanese knotweed (Polygonum cuspidatum), has documented in vitro activity against B. burgdorferi log-phase spirochetes and B. garinii. It inhibits NF-κB-driven pro-inflammatory cytokines, crosses the blood-brain barrier to address neurological Lyme, and inhibits matrix metalloproteinases used by Borrelia for tissue invasion. PMC studies confirm direct anti-spirochetal and anti-inflammatory mechanisms relevant to Lyme disease.
Resveratrol is a stilbenoid polyphenol with anti-angiogenic, anti-inflammatory, and antioxidant properties that address multiple AMD pathways. A Phase 2 RCT (n=32, 24-month follow-up) testing oral resveratrol, quercetin, and curcumin (RQC) in intermediate AMD patients reported a 2.5% mean decrease in drusen volume in the RQC group vs. a 5% increase in the curcumin-only group, suggesting drusen-reducing potential. Further independent large-scale trials are needed.
Resveratrol inhibits FcεRI-mediated mast cell degranulation and cytokine/chemokine expression dose-dependently in mature human intestinal mast cells isolated from surgical tissue, as published in PMC8307672. Mechanisms include blockade of mitochondrial and nuclear ERK1/2 and STAT3 phosphorylation. Animal models confirm prevention of food allergy and atopic dermatitis mediated by mast cell activity.
Resveratrol is a polyphenolic stilbene found in grapes and berries studied for neuroprotection and memory support. A 2017 double-blind RCT (n=60, age 50–75, 200 mg/day, 26 weeks) found resveratrol significantly improved word retention and verbal memory versus placebo. Mechanisms include SIRT1 activation, amyloid-β clearance, cerebrovascular protection, and BDNF upregulation.
Resveratrol has been studied across multiple menopausal endpoints in human RCTs. The 24-month RESHAW trial found improvements in cognitive function, cerebrovascular reactivity, bone mineral density, pain, and well-being in 125 postmenopausal women taking 75 mg twice daily. Smaller trials support benefits for vasomotor symptoms, sleep, and mood. A systematic review across nearly 200 clinical trials recognizes menopause symptoms as one of resveratrol's studied indications.
Resveratrol has been extensively studied in human clinical trials for its effects on metabolic syndrome (MetS) components including blood pressure, glucose, lipids, and body composition. Preclinical evidence is robust, but human trial results are mixed and often inconclusive. A 2024 meta-analysis found significant reductions in systolic and diastolic blood pressure, while effects on waist circumference, HDL, and triglycerides were inconsistent or unfavorable. One well-powered RCT found no benefit—and some adverse lipid changes—at high doses in men with MetS.
Resveratrol, a polyphenol found in red grapes and red wine, has been studied extensively for its effects on metabolic health. Human clinical trials and meta-analyses demonstrate modest but consistent improvements in glucose levels, insulin sensitivity, triglycerides, waist circumference, and HDL cholesterol in individuals with metabolic syndrome. However, results across trials are mixed, and no consensus dosing regimen has been established for any metabolic indication.
Resveratrol, a polyphenol from grape skins, modulates DNA methylation by inhibiting DNMT activity and modulating TET enzymes, decreasing promoter methylation of specific genes. A 2025 PMC systematic review (PMC12554032) and PMC12841049 identify resveratrol among the food-derived bioactives with demonstrated effects on DNA methylation via DNMT inhibition. Evidence is primarily preclinical.
Resveratrol activates SIRT1 and AMPK pathways to promote mitochondrial biogenesis via PGC-1α, and has been studied as a therapeutic approach for mitochondrial disorders. Preclinical and early clinical data support its mitogenic, antioxidant, and anti-apoptotic activities relevant to mitochondrial health, particularly in OXPHOS-deficient models.
Resveratrol, a stilbenoid polyphenol from grapes and berries, has been specifically reviewed in a 2024 PMC publication for protective and detoxifying effects against zearalenone-mediated toxicity. It acts via antioxidant, anti-inflammatory, and anti-estrogenic mechanisms to counter mycotoxin-induced reproductive and hepatic damage. The PMC review concludes it is a promising natural mycotoxin detoxification agent with potential clinical applications.
Resveratrol activates SIRT1, AMPK, and Nrf2 pathways with anti-inflammatory and antioxidant properties relevant to muscle recovery. Pilot RCTs show reduced CK post-exercise at 250 mg/day; however, evidence in humans is mixed, with some high-quality RCTs showing potential blunting of exercise adaptations at higher doses.
Resveratrol, a stilbenoid polyphenol from grapes and berries, activates SIRT1 and inhibits NF-κB, producing anti-neuroinflammatory and neuroprotective effects relevant to peripheral neuropathy. A 2025 Frontiers in Pharmacology systematic review identified it as demonstrating anti-inflammatory effects through SIRT1 pathway activation relevant to neuropathy. Multiple rodent neuropathy models show resveratrol reduces pain behaviors and preserves nerve fiber density.
Resveratrol activates SIRT1 and modulates the ELAVL4-BDNF mRNA pathway, promoting synaptic plasticity and neuroplasticity. A 2025 PMC study identified the ELAVL4-Bdnf mRNA pathway as the mechanistic link between resveratrol's antidepressant effects and neuroplasticity. It also activates AMPK/SIRT1 signaling relevant to neurogenesis.
Resveratrol activates eNOS through AMPK/SIRT1-dependent phosphorylation and antioxidant superoxide scavenging, enhancing endothelial NO production and bioavailability. It is well documented in natural products and eNOS literature as a modulator of endothelial NO synthesis, with cardiovascular evidence consistent with NO-mediated vasodilation.
Resveratrol is a polyphenol with evidence from a 12-month placebo-controlled RCT showing increased BMD at the lumbar spine and femoral neck and reduced bone resorption markers in postmenopausal women. A 24-month RCT in osteopenic postmenopausal women also provided clinical evidence of bone protection, with the greatest benefit in women with poor bone health biomarker status.
Resveratrol, a natural polyphenol, has been reviewed as a potential medical drug for acute pancreatitis due to its anti-inflammatory and antioxidant mechanisms. In animal studies it reduces TNF-α, IL-6, NF-κB activation, serum amylase, and pancreatic microvascular damage. A 2021 comprehensive review concluded it may attenuate AP and its complications through cytokine suppression.
Resveratrol, a polyphenol from grapes and red wine, has demonstrated neuroprotective effects in Parkinson's disease models by activating SIRT1, reducing oxidative stress, inhibiting neuroinflammation, and protecting dopaminergic neurons. Preclinical studies show it inhibits LPS-induced neuroinflammation and protects DA neurons in 6-OHDA rodent PD models. Clinical evidence is still early.
Resveratrol, a polyphenol found in grapes and berries, has been studied in multiple RCTs for PCOS. Clinical trials demonstrated reductions in total testosterone, DHEA-S, and fasting insulin at doses of 1,000–1,500mg/day, along with improved menstrual regularity and insulin sensitivity.
Resveratrol was directly tested in an acetic acid-induced rat pleurisy model, significantly inhibiting white blood cell count and pleurisy exudates, decreasing nitric oxide production, and elevating superoxide dismutase activity in serum. These findings, published in PMC-indexed research, establish a direct preclinical evidence link between resveratrol and pleurisy. Resveratrol also inhibits NF-κB and COX-2 relevant to pleural inflammation.
Preclinical studies show resveratrol significantly reduced polyp number in ApcMin/+ mice (15–30 mg/kg) and in azoxymethane-injected rats (10–100 mg/kg) via LEF1 downregulation in the Wnt/β-catenin pathway. In vitro screening of 1,309 FDA-approved compounds using colorectal adenoma patient-derived organoids identified resveratrol as the strongest inhibitor of adenoma growth. Resveratrol also synergizes with curcumin against colorectal cancer cells in vivo.
A polyphenol stilbene from grapes and Japanese knotweed, resveratrol activates SIRT1 and AMPK pathways supporting cellular energy recovery, anti-inflammatory activity, and mitochondrial biogenesis relevant to post-illness recovery. Clinical studies document anti-inflammatory effects and improvements in metabolic recovery markers.
Resveratrol is a polyphenol stilbenoid with antioxidant and anti-inflammatory actions that has been included in post-viral recovery protocols and is under clinical trial investigation for long COVID. The VA Long COVID guide (2023) mentions resveratrol among supplements under clinical trial investigation. It activates SIRT1 and AMPK, supports mitochondrial biogenesis, and reduces NF-κB inflammatory signaling relevant to post-viral fatigue.
Resveratrol, a stilbenoid found in grape skins and Japanese knotweed, has antitumor activity in prostate cancer cells via anti-androgenic, pro-apoptotic, and antioxidant mechanisms. Preclinical and early-phase clinical studies support its role in prostate cancer chemoprevention. An RCT examined high vs. low doses in PSA-recurrent prostate cancer patients. Evidence supports biological activity but not proven clinical efficacy.
Resveratrol has been studied for psoriasis in preclinical models and limited in vitro studies. It inhibits IL-17A, TNF-α, and COX-2, activates SIRT1 signaling, and promotes keratinocyte differentiation. Mouse studies show significant reduction in psoriasis-like skin lesions. Current evidence is preclinical; no published human RCTs are available.
Resveratrol is a polyphenolic stilbenoid that inhibits NF-κB, COX-2, and inflammatory cytokines relevant to RA. A 2025 network meta-analysis of 18 RA RCTs ranked resveratrol as the most effective plant substance for reducing DAS28 disease activity score (SUCRA 74.3%), a primary clinical outcome in RA.
A clinical study (Ferzli et al., J Drugs Dermatol 2013) combining topical resveratrol, green tea polyphenols, and caffeine found meaningful improvement in facial redness in 16 rosacea patients over 6 weeks. Resveratrol is reviewed as a biologically-based rosacea therapy in J Drugs Dermatol 2018 (PMID 29879248) alongside niacinamide, green tea, and zinc.
Resveratrol has demonstrated anti-scarring effects in vitro and in vivo by arresting fibroblast cell cycle at G1, reducing hypertrophic scar fibroblast proliferation, decreasing collagen types I and III, and downregulating TGF-β1 and alpha-smooth muscle actin. One RCT (rated 2b) supports clinical use for scar management.
Trans-resveratrol, a polyphenolic stilbenoid from grapes, has been evaluated both topically and orally for skin aging. A 2025 RCT demonstrated that oral and/or topical trans-resveratrol reduced visible signs of aging in healthy women over 40 after 8 weeks. A topical formulation with 1% trans-resveratrol showed significant improvements in fine lines, wrinkles, firmness, and elasticity over 12 weeks.
Resveratrol is a stilbene polyphenol with clinical and mechanistic evidence for stimulating collagen and elastin synthesis while inhibiting MMP-mediated collagen degradation. A 12-week oral resveratrol trial for mild photoaging showed improvements in skin firmness and elasticity. Emerging data support its value as a co-supplement with collagen peptides for enhanced skin elasticity outcomes.
Resveratrol is a polyphenol stilbenoid with antioxidant, anti-inflammatory, and vasoprotective properties studied in the context of chronic venous disease. It is found in red vine leaf extract (Antistax), a documented venoactive product for CVI and related vascular conditions including spider veins. Authoritative PMC reviews list it as a relevant compound in venous disease management.
Resveratrol, a stilbenoid from grape skins, suppresses UV-induced tumorigenesis and reduces inflammatory mediators (IL-6, COX-2). Topical resveratrol was shown in 1997 to prevent skin cancer development in carcinogen-treated mice. Human dietary grape studies showed resveratrol-containing polyphenols reduced UV-induced pro-inflammatory cytokines via multiple pathways.
Resveratrol, a stilbenoid polyphenol from red grapes and Polygonum cuspidatum, has been shown in multiple meta-analyses of RCTs to significantly reduce serum triglycerides. It activates SIRT1 and AMPK, inhibiting lipogenic pathways and promoting fatty acid oxidation.
Resveratrol has demonstrated anti-uterine fibroid activity in preclinical models. In vitro and in vivo studies show it inhibits leiomyoma cell proliferation, induces apoptosis, reduces extracellular matrix protein expression, and suppresses tumor growth in mouse xenograft models. It is included among the natural compounds under investigation for uterine fibroid management.
Resveratrol is a polyphenol stilbene found in grapes and red wine with documented antiviral activity against influenza, SARS-CoV-2, EBV, and other viruses. It blocks viral RNA nuclear-cytoplasmic translocation, suppresses viral replication, and modulates immunity via SIRT1 and NF-κB pathways. In vitro evidence is strong; human data are emerging.
Resveratrol is a stilbenoid polyphenol found in grapes, Japanese knotweed, and red wine. In cell models it inhibits 5-alpha reductase activity and promotes dermal papilla cell proliferation via Wnt/beta-catenin signaling. Animal studies show topical resveratrol extends the anagen phase. It is included in hair loss supplement formulations based on mechanistic and preclinical data.
Volver